These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 2407093)

  • 21. Moricizine: a new class I antiarrhythmic.
    Mann HJ
    Clin Pharm; 1990 Nov; 9(11):842-52. PubMed ID: 2272151
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of moricizine in malignant ventricular arrhythmias.
    Horowitz LN
    Am J Cardiol; 1990 Feb; 65(8):41D-46D; discussion 68D-71D. PubMed ID: 1689535
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence and characteristics of proarrhythmia from moricizine (Ethmozine).
    Morganroth J; Pratt CM
    Am J Cardiol; 1989 Jan; 63(3):172-6. PubMed ID: 2642632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of Ethmozine (moricizine HCl) on ventricular function using echocardiographic, hemodynamic and radionuclide assessments.
    Pratt CM; Podrid PJ; Seals AA; Young JB; Hession M; Lampert S; Quiñones M; Lown B
    Am J Cardiol; 1987 Oct; 60(11):73F-78F. PubMed ID: 3310589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy, safety, hemodynamic effects, and pharmacokinetics of high-dose moricizine during short- and long-term therapy.
    Salerno DM; Sharkey PJ; Granrud GA; Asinger RW; Hodges M
    Clin Pharmacol Ther; 1987 Aug; 42(2):201-9. PubMed ID: 3301153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum digoxin concentrations during ethmozine antiarrhythmic therapy.
    Kennedy HL; Sprague MK; Redd RM; Wiens RD; Blum RI; Buckingham TA
    Am Heart J; 1986 Apr; 111(4):667-72. PubMed ID: 2420164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiarrhythmic efficacy of Ethmozine (moricizine HCl) compared with disopyramide and propranolol.
    Pratt CM; Butman SM; Young JB; Knoll M; English LD
    Am J Cardiol; 1987 Oct; 60(11):52F-58F. PubMed ID: 3310586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early and late proarrhythmia from antiarrhythmic drug therapy.
    Morganroth J
    Cardiovasc Drugs Ther; 1992 Feb; 6(1):11-4. PubMed ID: 1533532
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implications of the Cardiac Arrhythmia Suppression Trial for antiarrhythmic drug treatment.
    Bigger JT
    Am J Cardiol; 1990 Feb; 65(8):3D-10D; discussion 68D-71D. PubMed ID: 2106253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The antiarrhythmic drug Etmozine in the light of new findings].
    Mádle A
    Vnitr Lek; 1987 Sep; 33(9):810-5. PubMed ID: 3314125
    [No Abstract]   [Full Text] [Related]  

  • 31. Investigational antiarrhythmic drugs for the treatment of ventricular rhythm disturbances.
    Pratt CM; Luck JC; Mann DE; Wyndham CR
    Cardiol Clin; 1984 Feb; 2(1):35-46. PubMed ID: 6443563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The natural history of benign and potentially malignant ventricular arrhythmias with special reference to nonsustained ventricular tachycardia.
    Pratt CM; Francis M; Mahler S; Aogaichi K; Keus P; Young JB
    Am Heart J; 1988 Oct; 116(4):897-903. PubMed ID: 2459950
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complex ventricular arrhythmias associated with the mitral valve prolapse syndrome. Effectiveness of moricizine (Ethmozine) in patients resistant to conventional antiarrhythmics.
    Pratt CM; Young JB; Wierman AM; Borland RM; Seals AA; Leon CA; Raizner A; Quinones MA; Roberts R
    Am J Med; 1986 Apr; 80(4):626-32. PubMed ID: 3515932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of moricizine hydrochloride in reducing chronic high-frequency ventricular arrhythmia: results of a prospective, controlled trial.
    Singh SN; DiBianco R; Gottdiener JS; Ginsberg R; Fletcher RD
    Am J Cardiol; 1984 Mar; 53(6):745-50. PubMed ID: 6367416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New drugs in the management of ventricular arrhythmias.
    Sanna GP
    G Ital Cardiol; 1984 Oct; 14(10):788-97. PubMed ID: 6083894
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and toxicity of antiarrhythmic drug therapy: benefit versus risk.
    Podrid PJ
    J Cardiovasc Pharmacol; 1991; 17 Suppl 6():S65-73. PubMed ID: 1723122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of antiarrhythmic therapy using Holter monitoring.
    Morganroth J
    Am J Cardiol; 1988 Oct; 62(12):18H-23H. PubMed ID: 3052004
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and risks of moricizine in inducible sustained ventricular tachycardia.
    Damle R; Levine J; Matos J; Greenberg S; Brooks R; Frumkin W; Goldberger J; Kadish AH
    Ann Intern Med; 1992 Mar; 116(5):375-81. PubMed ID: 1736770
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A symposium: Pharmacological management of ventricular arrhythmias--current status in the role of moricizine HCl. October 19-22, 1989, Scottsdale, Arizona. Proceedings.
    Am J Cardiol; 1990 Feb; 65(8):1D-71D. PubMed ID: 2407087
    [No Abstract]   [Full Text] [Related]  

  • 40. From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials.
    Lazzara R
    Am J Cardiol; 1996 Aug; 78(4A):28-33. PubMed ID: 8780326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.